Omeprazole (A2845): Technical Guidance for Research Workflows

What This Product Solves

Omeprazole (SKU: A2845), chemically defined as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a highly specific H+,K+-ATPase inhibitor for research applications. This compound is widely used in gastric acid secretion research, enabling precise investigation of proton pump function and antiulcer activity in preclinical models. Its robust inhibition profile (IC₅₀ for H+,K+-ATPase: 5.8 μM) supports the study of mechanisms underlying gastric acid-related disorders and facilitates modeling in peptic ulcer disease workflows. Not intended for diagnostic or medical use, Omeprazole is supplied at high purity and under rigorously controlled conditions to ensure experimental reliability. For a detailed overview of its chemical and workflow advantages, see the internal article here, which explains its benchmarking role in antiulcer activity study design.

Protocol Parameters

• In vitro H+,K+-ATPase inhibition assay | IC₅₀ = 5.8 μM | Directly applicable to proton pump inhibition studies | Enables quantitative assessment of enzyme inhibition dynamics | Product dossier
• Histamine-induced gastric acid formation inhibition | IC₅₀ = 0.16 μM | Useful for modeling gastric acid secretion in cellular or tissue systems | Facilitates evaluation of antiulcer candidate efficacy under physiologically relevant triggers | Product dossier
• Solubility in DMSO | ≥17.27 mg/mL | Suitable for DMSO-based stock preparation in assay workflows | Ensures adequate working concentrations for dose-response and mechanistic studies; avoid aqueous or ethanol solvents due to poor solubility | Product dossier
• Recommended storage (solid) | -20°C | Essential for long-term compound stability | Maintains compound integrity and prevents degradation; solution storage not recommended | Product dossier

Workflow Setup and QC Checklist

To maximize reproducibility and data integrity in gastric acid secretion or antiulcer activity studies using Omeprazole (A2845), follow these technical workflow guidelines:

• Preparation: Dissolve Omeprazole in DMSO at concentrations suited to your assay (up to 17.27 mg/mL). Avoid water and ethanol as solvents to prevent precipitation and ensure complete dissolution.
• Aliquoting: Prepare single-use aliquots to minimize freeze-thaw cycles and reduce the risk of compound degradation.
• Storage: Store the solid product at -20°C. For best results, avoid storing solutions for extended periods; prepare fresh solutions prior to each experiment.
• Quality Control: Confirm product purity (>98%) as specified. Check for visible precipitates or discoloration before use.
• Shipping: Receive shipments on blue ice as indicated for small molecules to maintain stability during transit.
• Documentation: Record lot number and preparation details for batch-to-batch traceability, a key practice highlighted in this technical guide.

Common Failure Modes and Fixes

• Incomplete dissolution: If Omeprazole fails to dissolve in DMSO, verify solvent freshness and temperature. Sonication or gentle warming may assist complete solubilization. Avoid water or ethanol, as the compound is insoluble in these solvents.
• Compound degradation: Repeated freeze-thaw cycles or prolonged storage in solution can lead to potency loss. Always use freshly prepared DMSO stocks and limit solution storage to the shortest practical duration.
• Precipitation in assay buffer: Omeprazole may precipitate upon dilution in aqueous buffers. To minimize, add DMSO stock dropwise into well-mixed assay buffer with continuous stirring, and keep final DMSO concentrations below cytotoxicity thresholds for your model.
• Variable activity in cell-based models: Confirm that assay pH and buffer composition are compatible with Omeprazole’s chemical properties. Adjusting pH or buffer strength may improve assay consistency.

Scope and Limitations

• Intended use: Omeprazole (A2845) is intended strictly for laboratory research applications related to gastric acid secretion mechanisms, antiulcer drug development, and proton pump inhibition.
• Not for diagnostic or clinical use: The compound must not be used for patient diagnostics, therapeutic interventions, or any clinical protocols.
• Solvent compatibility: Use only DMSO for stock solutions. Poor solubility in water and ethanol limits its applicability in workflows requiring these solvents.
• Model system boundaries: While effective in preclinical and in vitro settings, application to non-gastric or off-target models is not supported by the available product dossier.

Conclusion

Omeprazole (A2845) is a well-characterized, high-purity H+,K+-ATPase inhibitor optimized for controlled research environments. By adhering to recommended dissolution, storage, and workflow practices, researchers can ensure robust, reproducible data in gastric acid secretion and antiulcer activity studies. For further reading on workflow enhancements and troubleshooting, refer to the article here, which outlines protocol optimizations and advanced applications in peptic ulcer disease models. For ordering and full technical details, visit the Omeprazole product page.